2006 marks the 40th year of publication for The Annals. Over that time, The Annals has been an important contributor to the development of clinical pharmacy. Throughout 2006, we are publishing articles reflecting on the history of clinical pharmacy through the eyes of practitioners, including those pioneering clinical pharmacy, as well as those who have more recently entered the profession and a well-established specialty. In addition, we are also presenting articles and editorials from the early history of The Annals that have given direction and shape to the practice of clinical pharmacy (see page 2240).
Get full access to this article
View all access options for this article.
References
1.
KurtzkeJF, BennettDR, BergBO, BeringerGB, GoldsteinM, VatesTSJr.Neurologists in the United States—past, present, and future. Neurology1986;36:1576-82.
RichensA.A study of the pharmacokinetics of phenytoin (diphenylhydantoin) in epileptic patients, and the development of a nomogram for making dose increments. Epilepsia1975;16:627-46.
5.
HussarDA. Therapeutic incompatibilities: drug interactions. Am J Pharm Sci Support Public Health1967;139:215-33.
6.
KuttH, LouisS.Anticonvulsant drugs. II. Clinical pharmacological and therapeutic aspects. Drugs1972;4:256-82.
7.
LuddenTM. Individualization of phenytoin therapy (letter). J Pharm Pharmacol1980;32:152.
8.
MullenPW, FosterRW. Comparative evaluation of six techniques for determining the Michaelis–Menten parameters relating phenytoin dose and steady-state serum concentrations. J Pharm Pharmacol1979;31:100-4.
9.
PriviteraMD. Clinical rules for phenytoin dosing. Ann Pharmacother1993;27:1169-73.
10.
WeltyTE, RobinsonFC, MayerPR. A comparison of phenytoin dosing methods in private practice seizure patients. Epilepsia1986;27:76-80.
11.
CloydJC, GumnitRJ, McLainLWJr.Status epilepticus. The role of intravenous phenytoin. JAMA1980;244:1479-81.
12.
AlldredgeBK, GelbAM, IsaacsSM,. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med2001;345:631-7.
13.
RyanM, Gora-HarperML, CaldwellF.Experience with an adverse drug reaction reporting program in a neurology specialty clinic. Ann Pharmacother2002;36:231-5. DOI 10.1345/aph.1Z430
14.
Directory of Residencies, Fellowships, and Graduate Programs.American College of Clinical Pharmacy. www.accp.com/resandfel/directorynon.php (accessed 2006Aug 31).
